留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

"Polypill"的发展及前景

向丽 姜鹏 胡耀华 王淑萍 张卫东 柳润辉

向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. 'Polypill'的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
引用本文: 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. "Polypill"的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
Citation: XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001

"Polypill"的发展及前景

doi: 10.3969/j.issn.1006-0111.2012.03.001

Progress and prospect on Polypill

  • 摘要: 慢性疾病的发病率越来越高,尤其是心脑血管疾病,已成为人类死亡的首要原因。由于心脑血管疾病是由多种危险因素诱发,仅仅使用单一的药物远远不能达到预防或治疗的目的。基于此出现了多效药物"Polypill"的概念,具有使用方便、成本低、提高了患者对药物的依从性等特点。本文就"Polypill"的研究发展及应用前景进行综述。
  • [1] Available from:http://www.who.int/cardiovascular diseases/en/.
    [2] Yusuf S,Reddy S,Ounpuu S,et al.Global burden of cardiovascular disease:part Ⅱ:variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J].Circulation,2001,104(23):2855.
    [3] Bonow RO,Smaha LA,Smith SC,et al.The international burden of cardiovascular disease: responding to the emerging global epidemic[J].Circulation 2002,106:1602.
    [4] Yusuf S. Two decades of progress in preventing vascular disease[J].Lancet,2002360(9326):2.
    [5] Wald NJ,Law MR.A strategy to reduce cardiovascular disease by more than 80%[J]. BMJ,2003,326(7404):1419.
    [6] Jennifer GR.A"Poly-Portfolio" for Secondary Prevention: A strategy to reduce subsequent events by up to 97% over five years[J]. Am J Cardiol,2005,95(3):373.
    [7] Thomas AG, Lionel HO, Milton CW.Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis[J].Lancet.2006,19:679.
    [8] Vijay K, Ravi PS, Saranjit S.LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases Part 1. Separation of active components and classification of their interaction/degradation products[J].J Pharmaceut Blomed, 2008,47:508.
    [9] Vijay K, Bhagwat P, Saranjit S.Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases[J].D Drug Dev. Ind. Pharm,2008,5(1): 63.
    [10] Yusuf S,Pais PEffects of a polypill(Polycap)on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase 11, double-blind, randomised trial[J].Lancet, 2009,373(9672):1341.
    [11] Davey SG, Ebrahim S. Folate supplementation and cardiovascular disease[J].Lancet, 2005,366:1679.
    [12] Rastegarpanah M, Malekzadeh F, Thomas GN, et al.A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?[J].Archivs of Iranian Medicine, 2008,11(3):306.
    [13] Salerno CM, Demopoulos L, Mukherjee R, et al.Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension[J].J Clin Hypertens,2004,6:614.
    [14] Leventhal MJ, Riegel B, Carlson B, el al.Negotiating compliance in heart failure: Remaining issues and questions[J].Eur J Cardiovase Nurs,2005,4:298.
    [15] Newby LK, La PNM, Chen AY, et al.Long term adherence to evidencebased secondary prevention therapies in coronary artery disease[J].Circulation,2006,113(2):203.
    [16] 曹东来,扬向军.PCI术后冠心病病人他汀类药依从性分析[J].中国血液流变学杂志,2004,14(1):126.
    [17] Fuster V, Voute J. MDGs: chronic diseases are not on the agenda[J].Lancet,2005,366:1512.
    [18] Murray CJL, Lauer JA, Hutubessy RC, et al.Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk[J].Lancet,2003;361:717.
    [19] Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study[J].Lancet, 2004,364:937.
    [20] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials[J]. BMJ,2003,326:1427.
    [21] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. CURR OPIN LIPIDOL.2009,20(6):453.
    [22] Frishman WH, Ztmkerman AL.Amlodi pjne/atovrastatin: tile first cross risk factor polypill for tile prevention and treatment of caldiovaseular disease[J].Expert Prey Cardiovasc Ther,2004,2675:681.
    [23] Zwolska Z, Niemirowska H, Augustynowicz E, et al.Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules[J].Int J Tuberc Lung Dis,2(10):824.
    [24] Kulkanya C, Nottasorn P, Tim RC, et al.Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine[J]. AIDS,2005,19:1495.
    [25] Freedberg KA, Losina E, Weinstein MC, et al.The cost effectiveness of combination antiretroviral therapy for HIV disease[J].N Engl J Med,2001,334:824.
    [26] Bakshi R, Hermeling I, Gathmann I, et al.An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug[J]. T Roy Soc Trop Med H,2000,94:419.
    [27] Valentin F.Prime time for a polypill after myocardial infraction[J]. Nat Clin Pract Card,2009,6:83.
    [28] http://www.emea.europa.eu/htms/human/epar/a.htm.
    [29] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. Curr Opin Lipidol 2009,20(6):453.
    [30] Pearson TA, Blair SN, Daniels SR, et al.AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases[J].Circulation,2002,106:388.
    [31] Jha P, Peto R, Zatonsky W, et al.Social inequalities in male mortality and in male mortality from smoking: indirect estimation natio from nal death rates in England and Wales, Poland, and North america[J].Lancet,2006,368:367.
    [32] NCEP Expert Panel.Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III)[J].JAMA,2001,285:2486.
    [33] Williams PT.Physical fitness and activity as separate heart disease risk factors: a meta-analysis[J].Med Sci Sports Exerc,2001,33:754.
    [34] Blair SN, Kampert JB, Kohl HW III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women[J].JAMA,1996,276:205.
  • [1] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [2] 张广雨, 杜晶, 刘梦珍, 朱丹妮, 闫慧, 刘冲.  新斯的明与山莨菪碱联合应用对肺型氧中毒的作用及其机制的研究 . 药学实践与服务, 2024, 42(8): 1-7. doi: 10.12206/j.issn.2097-2024.202310049
    [3] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [4] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [5] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [6] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [7] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 1-6. doi: 10.12206/j.issn.2097-2024.202308062
    [8] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [9] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
    [10] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
  • 加载中
计量
  • 文章访问数:  4426
  • HTML全文浏览量:  310
  • PDF下载量:  922
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-04-26
  • 修回日期:  2011-12-18

"Polypill"的发展及前景

doi: 10.3969/j.issn.1006-0111.2012.03.001

摘要: 慢性疾病的发病率越来越高,尤其是心脑血管疾病,已成为人类死亡的首要原因。由于心脑血管疾病是由多种危险因素诱发,仅仅使用单一的药物远远不能达到预防或治疗的目的。基于此出现了多效药物"Polypill"的概念,具有使用方便、成本低、提高了患者对药物的依从性等特点。本文就"Polypill"的研究发展及应用前景进行综述。

English Abstract

向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. 'Polypill'的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
引用本文: 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. "Polypill"的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
Citation: XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
参考文献 (34)

目录

    /

    返回文章
    返回